首页> 外文OA文献 >Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

【2h】

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

机译：高危骨髓增生异常综合征患者的骨髓细胞减少不影响阿扎胞苷的耐受性或疗效

页面导航

著录项
相似文献
相关主题

著录项

作者
Seymour John F.; Bennett John M.; List Alan F.; Mufti Ghulam; Gore Steven D.; Fenaux Pierre; Santini Valeria; Hetzer Joel; Songer Stephen; Skikne Barry S.; Beach Charles L.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. [J] . John F Seymour, John M Bennett, Alan F List, British Journal of Haematology . 2014,第1期

机译：骨髓假细胞性不影响氮酰氨氨酸患者患者患有更高风险的骨髓增生综合征的耐受性或疗效。
2. Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naive & Relapsed (Rel)/Refractory (Ref) Patients [J] . Navada Shyamala C., Garcia-Manero Guillermo, Atallah Ehab L., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：口服Rigosertib的膨胀研究与患者（PTS）中的氮酰氨氨酸（AZA）结合较高风险（HR）髓细胞增强综合征（MDS）：HMA治疗Naivent＆Dresped（rel）/难以（REF）患者的疗效和安全结果
3. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group [J] . Papageorgiou Sotirios G., Vasilatou Diamantina, Kontos Christos K., American Journal of Hematology . 2018,第7期

机译：用5-氮杂辛胺治疗的骨髓增生综合征高风险患者单体核型（MK）的预后价值：Hellenic（希腊语）骨髓增强综合征研究组的回顾性分析
4. A Bayesian Review of the Meta-Analysis on the Efficacy of Bone Marrow-Derived Cells Transplantation in Adult Patients with Heart Diseases [C] . Siew-Pang Chan, Rosalind Lee, Kim-Leng Poh World Congress on Engineering . 2009

机译：贝叶斯审查骨髓源细胞移植在成人患者心脏病患者中的疗效综述
5. Chronic Bone Marrow Failure and Transfusion Patterns: Epidemiological Studies of Blood Transfusions and Outcomes in Patients with Myelodysplastic Syndromes [D] . Rydén, Jenny. 2021

机译：慢性骨髓衰竭和输血模式：骨髓增生综合征患者出血和结果的流行病学研究
6. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised open-label phase III study [O] . Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, -1

机译：与传统护理方案相比阿扎胞苷在治疗高危骨髓增生异常综合症中的疗效：一项随机开放标签的III期研究
7. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group [O] . Sotirios G. Papageorgiou, Diamantina Vasilatou, Christos K. Kontos, 2018

机译：用5-氮杂辛胺治疗的骨髓增生综合征高危患者单体核型（MK）的预后价值：Hellenic（希腊语）骨髓增生综合征研究组的回顾性分析

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

著录项

相似文献

相关主题

期刊订阅